ArticleJournal of neuro-oncology2026
Individualized prediction of brain metastasis risk in patients with breast cancer.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer patients have a high risk of brain and central nervous system metastases (BrM) and therefore have poor outcomes. This study aimed to assess the impact of clinico-genomic factors on BrM risk in breast cancer and develop validated nomograms for risk prediction.
methodsClinico-genomic data on breast cancer patients were obtained from the AACR GENIE Biopharma Collaborative. These data were split into training and testing sets by academic institution. Using the training set, risk of BrM was evaluated through multivariable Fine-Gray subdistribution hazard modeling, implementing LASSO penalization for feature selection. Prediction metrics were assessed internally on the training set through bootstrap-cross validation, and externally on the testing set. Calibration curves, AUC, and Brier scores were calculated to assess prediction and discrimination. A nomogram for 2-, 3.5-, and 5- year risk of BrM was constructed.
resultsSynchronous bone metastases, HER+/HR- breast cancer subtype, and TP53 alterations were selected as top predictors of BrM risk. The final multivariable model showed good discriminate capability at 2- (AUC: 68.7; Brier: 5.3), 3.5- (AUC: 65.9, Brier: 12.9), and 5-years (AUC 63.0, Brier: 17.4). This model was externally validated on the testing set and performed well at 2- (AUC 72.5; Brier: 10.5), 3.5- (AUC: 73.3; Brier 13.6), and 5-years (AUC: 74.9; Brier: 16.5).
conclusionsNomograms that calculate individualized BrM risk probabilities for patients with breast cancer can provide clinical utility informing patients and their health care team members on risk of BrM development. An interactive webtool for individualized BrM risk probabilities can be found here: https://gcioffi.shinyapps.io/BrCA_nomo_brm_risk/ .
Indexed as
Identifiers
41572090What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.